-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
Another monoclonal antibody to TNF-a has been approved for the treatment of Crohn's Disease.
-
Clinicians are becoming more attuned to the many complications of influenza, particularly with the high morbidity and mortality seen with H5N1 strains spreading around the world.
-
-
In 2007, the ACCF/AHA published a consensus statement in the Journal of the American College of Cardiology endorsing a role for coronary artery calcium scoring (CAC) in cardiovascular risk stratification.
-
One-time screening for abdominal aortic Aneurysms (AAA) is recommended in older men, but there is little long-term data on the value of such screening, especially in women.
-
For those women who were randomized to estrogen plus progesterone in the Women's Health Initiative Trial, the increased risk of breast cancer has persisted since stopping the replacement therapy, but the increased risk of cardiovascular events has returned to that of the placebo group.
-
Lifestyle changes such as improving diet and exercise are always the first important approach for the treatment of hyperlipidemia however, if the target LDL-C level is not achieved using statins and niacin, fibrates, and/or resins, at this time, ezetimibe should definitely be utilized to achieve these target goals if there are no specific contraindications to the use of the drug in each individual patient.
-
For 2 years beginning in February, 2005, every patient admitted to the Royal Infirmary of Edinburgh with community-acquired pneumonia (CAP) had blood levels of C-reactive protein (CRP) measured at the time of admission and (if still in the hospital) 4 days later. A standardized set of clinical and laboratory data was also acquired for each patient, per hospital routine.
-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend
millions to show the non-inferiority of their products compared to less
expensive, generic ACE inhibitors; some athletes turn to growth hormone
because it is difficult to detect; FDA Actions